Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498858 | 0.91 | HPGD (0.38) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL2496473 | 0.76 | TSHR (0.36) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL15103992 | 0.76 | CRHR1 (0.40) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL2495097 | 0.75 | CRHR1 (0.35) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL27051779 | 0.75 | HTT (0.41) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL2497127 | 0.75 | CRHR1 (0.38) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL2495319 | 0.74 | CRHR1 (0.39) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL15103887 | 0.73 | CRHR1 (0.39) | CRHR1HPGDPOLBKDM4EMAPT | |
| SCHEMBL2497003 | 0.72 | CRHR1 (0.39) | CRHR1HPGDKDM4EALDH1A1 | |
| SCHEMBL2502636 | 0.71 | CRHR1 (0.39) | CRHR1HPGDPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116322544-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116322544-A | Methods and compositions for treating polycystic ovary syndrome | 云杉生物科学公司 | 2023-06-23 | — | — | CN | disclosed |
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2094709-B1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885HPGD 1864/4885POLB 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.